LY03020
Phase 2Small molecule
Luye Pharma Group Ltd.LY03020 is one of 66 small molecule programs targeting Schizophrenia. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Inapsine
Jazz PharmaceuticalsPreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
LY03020
Luye Pharma Group Ltd.Phase 2
Catapres
Boehringer IngelheimPreclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Schizophrenia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY03020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company